Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TargomiRs
- Development stage
- Phase 1
- Lead developer
- Engeneic
- Modality
- Gene Therapies, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TargomiRs are a novel therapeutic platform consisting of nonliving bacterial minicells (nanoparticles) known as EnGeneIC Dream Vectors, which are loaded with a synthetic microRNA (miR-16-based mimic) and targeted to tumors via an epidermal growth factor receptor (EGFR)-specific antibody. The primary mechanism is the restoration of tumor-suppressive miR-15/miR-16 family function in cancer cells where these microRNAs are downregulated, leading to inhibition of oncogenic targets such as BCL2, CDK1, and JUN. The minicell delivery system protects the RNA payload from degradation and enables targeted delivery to EGFR-expressing tumor cells. TargomiRs have been primarily developed for malignant pleural mesothelioma but may have broader applications in oncology.
- Other names
- nanocell-encapsulated miR-16-based microRNA mimicEnGeneIC Dream Vectors loaded with miR-16 mimic
02
Targets
BCL-2 (BCL-2 family)Cyclin-dependent kinase 1 (CDK1) mRNAJUN (Transcription factor Jun)CDK1 (Cyclin-dependent kinase 1)FOS (Activator Protein 1)
Beyond the preview
Go deeper on TargomiRs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TargomiRs.